PMID- 32953720
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 15
DP  - 2020 Aug
TI  - Real-world data on the effectiveness and safety of interferon-alpha-2a 
      intralesional injection for the treatment of focally recalcitrant mycosis 
      fungoides.
PG  - 920
LID - 10.21037/atm-20-1458 [doi]
LID - 920
AB  - BACKGROUND: Focally recalcitrant mycosis fungoides (MF) is challenging to treat. 
      Despite interferon (IFN)-alpha intralesional injection having been tested in 
      randomized controlled trials for the treatment of patch or early plaque lesions 
      of MF, no real-world data regarding this therapy for focally recalcitrant MF has 
      been reported. This study aimed to evaluate the effectiveness and safety of 
      IFN-alpha-2a intralesional injection in focally recalcitrant MF. METHODS: Data on all 
      cases of focally recalcitrant MF treated by IFN-alpha-2a intralesional injection in 
      Peking Union Medical College Hospital from January 1, 2015 to December 31, 2019 
      were retrospectively retrieved. Based on clearance of injected lesions and the 
      proportion of adverse events (AEs), the effectiveness and safety of the treatment 
      were analyzed, respectively. RESULTS: Of the 15 patients included, 10 (66.7%) 
      achieved complete response (CR), and 1 (6.7%) patient had partial response. The 
      overall response rate was 73.3%. The clearance rate of lesions in the sun-exposed 
      areas was significantly higher than that in the non-sun-exposed areas (P<0.01). 
      The CR rate in patients with disease duration of less than 20 years was 
      significantly higher than that in the patients with disease duration of at least 
      20 years (P<0.05). Four (26.7%) patients had stable disease (SD). The median 
      event-free survival (EFS) was 4.0 months (95% CI, 1.8-6.1 months; range, 1-28+ 
      months). There were no severe acute or chronic side effects. CONCLUSIONS: 
      IFN-alpha-2a intralesional injection is an effective and safe treatment modality for 
      the treatment of focally recalcitrant MF.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Zhang, Shi-Yu
AU  - Zhang SY
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Liu, Zhao-Rui
AU  - Liu ZR
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Yang, Lu
AU  - Yang L
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Liu, Jie
AU  - Liu J
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Liu, Yue-Hua
AU  - Liu YH
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
FAU - Fang, Kai
AU  - Fang K
AD  - Department of Dermatology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7475424
OTO - NOTNLM
OT  - Interferon
OT  - intralesional injection
OT  - mycosis fungoides (MF)
OT  - therapy
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-1458). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/09/22 06:00
MHDA- 2020/09/22 06:01
PMCR- 2020/08/01
CRDT- 2020/09/21 06:17
PHST- 2020/09/21 06:17 [entrez]
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2020/09/22 06:01 [medline]
PHST- 2020/08/01 00:00 [pmc-release]
AID - atm-08-15-920 [pii]
AID - 10.21037/atm-20-1458 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 Aug;8(15):920. doi: 10.21037/atm-20-1458.